UroGen Pharma - URGN Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for UroGen Pharma in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" URGN shares.
View URGN analyst ratings or view top-rated stocks.

3 Wall Street research analysts have issued twelve-month target prices for UroGen Pharma's stock. Their URGN share price forecasts range from $11.00 to $23.00. On average, they expect the company's stock price to reach $18.00 in the next twelve months. This suggests a possible upside of 73.9% from the stock's current price.
View analysts price targets for URGN or view top-rated stocks among Wall Street analysts.

UroGen Pharma's stock was trading at $8.87 at the start of the year. Since then, URGN stock has increased by 16.7% and is now trading at $10.35.
View the best growth stocks for 2023 here.

UroGen Pharma saw a decrease in short interest in January. As of January 15th, there was short interest totaling 569,600 shares, a decrease of 15.2% from the December 31st total of 671,700 shares. Based on an average daily volume of 73,500 shares, the days-to-cover ratio is currently 7.7 days. Currently, 2.9% of the shares of the company are sold short.
View UroGen Pharma's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, March 20th 2023.
View our URGN earnings forecast.

UroGen Pharma Ltd. (NASDAQ:URGN) posted its quarterly earnings results on Thursday, November, 10th. The company reported ($1.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.22) by $0.09. The business had revenue of $16.10 million for the quarter, compared to analysts' expectations of $20.30 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other UroGen Pharma investors own include Sorrento Therapeutics (SRNE), Micron Technology (MU), OPKO Health (OPK), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Exelixis (EXEL), (KITE) (KITE), Syndax Pharmaceuticals (SNDX), AbbVie (ABBV) and Aytu BioPharma (AYTU).

(URGN) raised $46 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 3,500,000 shares at a price of $12.00-$14.00 per share. Jefferies and Cowen and Company served as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers.

UroGen Pharma trades on the NASDAQ under the ticker symbol "URGN."

UroGen Pharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (0.87%), Rice Hall James & Associates LLC (0.32%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Elizabeth A Barrett, Jason Drew Smith, Mark Schoenberg, Molly Henderson, Peter P Pfreundschuh and Stephen Mullennix.
View institutional ownership trends.

Shares of URGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of URGN stock can currently be purchased for approximately $10.35.

UroGen Pharma (NASDAQ:URGN) has a market capitalization of $235.36 million and generates $48.04 million in revenue each year. The company earns $-110,820,000.00 in net income (profit) each year or ($4.83) on an earnings per share basis.

The company employs 195 workers across the globe.

UroGen Pharma's mailing address is 400 Alexander Park, Princeton NJ, 08540. The official website for the company is www.urogen.com. The company can be reached via phone at (646) 768-9780 or via email at kate.bechtold@urogen.com.